Previous 10 | Next 10 |
home / stock / chgcy / chgcy news
Roche (OTCQX:RHHBY) is closing a patent infringement suit against AstraZeneca (NASDAQ:AZN) related to the rare disease medicine Ultomiris, Fierce Pharma reported. AstraZeneca had inherited the rare disease drug Ultomiris after acquiring Alexion Pharmaceuticals. Roche’s C...
Gilead’s (NASDAQ:GILD) COVID-19 therapy remdesivir has claimed the top spot, overtaking AbbVie’s (NYSE:ABBV) anti-inflammatory medication Humira in a list of drugs compiled by the purchasing group Vizient Inc, based on the spending of its member hospitals. From October...
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q3 2021 Earnings Conference Call October 22, 2021 5:00 AM ET Company Participants Osamu Okuda - President & Chief Executive Officer Toshiaki Itagaki - Executive Vice President & Chief Financial Officer Tetsuya Yamaguchi - Senior Vice President, ...
The following slide deck was published by Chugai Pharmaceutical Co., Ltd. in conjunction with their 2021 Q3 earnings call. For further details see: Chugai Pharmaceutical Co., Ltd. 2021 Q3 - Results - Earnings Call Presentation
Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Total return for Harding Loevner International Equity Fund net of fees was 5.43% vs. MSCI All Country World ex-US ...
Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affiliated Managers Group. The Glob...
The following slide deck was published by Chugai Pharmaceutical Co., Ltd. in conjunction with their 2021 Q2 earnings call. For further details see: Chugai Pharmaceutical Co., Ltd. 2021 Q2 - Results - Earnings Call Presentation
Roche (RHHBY) has been granted Marketing Authorization from the European Commission for Enspryng (satralizumab), created by Chugai Pharmaceutical (CHGCF), as the first subcutaneous treatment option for adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP...
Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. The current low-quality rally offers an opportunity to look back on the lessons from the last time the markets coo...
Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. The current low-quality rally offers an opportunity to look back on the lessons from the last time the markets coo...
News, Short Squeeze, Breakout and More Instantly...
Chugai Pharmaceuticals Co. Ltd. ADR Company Name:
CHGCY Stock Symbol:
OTCMKTS Market:
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
IDW Media Holdings, Inc. (IDWM) is expected to report for quarter end 2023-10-31 Deluxe Corporation (DLX) is expected to report $0.62 for Q4 2023 SkyWest Inc. (SKYW) is expected to report $0.11 for Q4 2023 1-800-FLOWERS.COM Inc. (FLWS) is expected to report $1.22 for Q2 2024 Brook...
Grandsouth Bancorporation (GRRB) is expected to report for quarter end 2023-09-30 Cadence Bank (CADE) is expected to report $0.56 for Q3 2023 Enterprise Financial Services Corporation (EFSC) is expected to report $1.24 for Q3 2023 Blackhawk Bancorp Inc. (BHWB) is expected to report fo...